F
$ Value
$6.5M
Shares
27,270
Price
$240
Filed
Feb 9
Insider
Name
Wengel Kathryn E
Title
EVP, Chief TO and Risk Officer
CIK
0001745955
Roles
Officer
Transaction Details
Transaction Date
2026-02-06
Code
F
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
105,956
Footnotes
Reflects the auto-exercise of options immediately prior to their expiration. | Shares withheld for payment of the exercise price and taxes in connection with the exercise of the options reported on this Form 4. | Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (1/31/2026). | Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (1/31/2026).
Filing Info
Wengel Kathryn E's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | F | $75K |
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | F | $79K |
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | A | $0 |
| 2026-02-15 | JNJ | A | $0 |
| 2026-02-13 | JNJ | M | $0 |
| 2026-02-13 | JNJ | F | $53K |
Other Insiders at JNJ (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
REED JOHN C
EVP, Innovative Medicine, R&D
|
— | $13.1M | 2026-02-17 |
|
Duato Joaquin
CEO and Chairman of the Board
|
— | $22.1M | 2026-02-15 |
|
Wolk Joseph J
Exec VP, CFO
|
— | $21.8M | 2026-02-17 |
|
Taubert Jennifer L
EVP, WWC. Innovative Medicine
|
— | — | 2026-02-15 |
|
Wengel Kathryn E
EVP, Chief TO and Risk Officer
|
— | — | 2026-02-15 |
|
Decker Robert J
VP Corporate Controller
|
— | — | 2026-02-15 |
|
Swanson James D.
EVP, CIO
|
— | $15.1M | 2026-02-17 |
|
Broadhurst Vanessa
EVP, Global Corp Affairs
|
— | $1.5M | 2026-02-17 |
|
Forminard Elizabeth
EVP, Chief Legal Officer
|
— | — | 2026-02-15 |
|
Schmid Timothy
EVP, WW Chair, MedTech
|
— | $5.5M | 2026-02-18 |
|
Mulholland Kristen
EVP, Chief HR Officer
|
— | — | 2026-02-15 |